scispace - formally typeset
Y

Yasuo Yanagi

Researcher at National University of Singapore

Publications -  184
Citations -  10971

Yasuo Yanagi is an academic researcher from National University of Singapore. The author has contributed to research in topics: Macular degeneration & Choroidal neovascularization. The author has an hindex of 37, co-authored 162 publications receiving 9836 citations. Previous affiliations of Yasuo Yanagi include Yokohama City University Medical Center & Asahikawa Medical University.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Convergence of Transforming Growth Factor-β and Vitamin D Signaling Pathways on SMAD Transcriptional Coactivators

Junn Yanagisawa, +9 more
- 26 Feb 1999 - 
TL;DR: Smad3, one of the SMAD proteins downstream in the TGF-beta signaling pathway, was found in mammalian cells to act as a coactivator specific for ligand-induced transactivation of VDR by forming a complex with a member of the steroid receptor coactivATOR-1 protein family in the nucleus.
Journal ArticleDOI

Light-induced gene transfer from packaged DNA enveloped in a dendrimeric photosensitizer

Nobuhiro Nishiyama, +10 more
- 20 Nov 2005 - 
TL;DR: This work demonstrates a new biomedical application for dendrimers, and the first success in the photochemical-internalization-mediated gene delivery in vivo, in which these two components are assembled into one structure.
Journal ArticleDOI

Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians.

Chee Wai Wong, +6 more
- 01 Jul 2016 - 
TL;DR: Current clinical trials of intravitreal anti-VEGF therapy and photodynamic therapy will provide clearer perspectives of evidence-based management of PCV and may lead to paradigm shifts in therapeutic strategies away from those currently employed in the treatment of CNV-AMD.
Journal ArticleDOI

Subretinal transplantation of bone marrow mesenchymal stem cells delays retinal degeneration in the RCS rat model of retinal degeneration.

Yuji Inoue, +7 more
- 01 Aug 2007 - 
TL;DR: Results suggest that MSC is a useful cell source for cell-replacement therapy for some forms of retinal degeneration, and secreted factor(s) from the MSCs promote photoreceptor cell survival.